300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Andorra
Guernsey
Cameroon
Sudan
Colombia
China
Armenia
Kenya
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Botswana
Moldova
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Aier Eye Hospital Group, VC Fund

Aier Eye Hospital Group

VC Fund

Changsha, China

Aier Eye Hospital Group is a VC fund in Changsha focused on Medical Device and Medical. Aier Eye Hospital Group offers surgery for myopia; prevention and treatment for myopia; treatment for cataract, glaucoma, pediatric ophthalmology, fundus disease, lacrimal disease, and cornea and ocular surface; and eye shaping beauty services.

Total investments:
10
Last investment:
Lead investor:
30%

Last updated:

Industries Aier Eye Hospital Group invests in

Medical DeviceMedicalSoftwareHealth CareBiotechnology

Stages Aier Eye Hospital Group invests in

Series ASeries BPost-IPO EquitySeedSeries C

Countries Aier Eye Hospital Group invests in

ChinaHong Kong

Contacts

NameEmailPhoneSocials
Bang Chen
Li Li
Michael Lau

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Medical Device 3 (30%)
  • Medical 2 (20%)
  • Software 2 (20%)
  • Health Care 2 (20%)
  • Biotechnology 2 (20%)
See all 18 industries →

Stage

  • Series A 2 (20%)
  • Series B 2 (20%)
  • Post-IPO Equity 2 (20%)
  • Seed 1 (10%)
  • Series C 1 (10%)
See all 7 stages →

Country

  • China 7 (70%)
  • Hong Kong 1 (10%)

Team

NameTitleInvestmentsLinksEmail
Bang Chen Founder
Founder Total investments: 0 Find email
Li Li Founder
Founder Total investments: 0 Find email
Michael Lau CEO
CEO Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Kangdesai Medical Technology Kangdesai Medical Technology
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrenceand metastasis. Series A / Sep 22, 2025
Sieran Medical
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. $14.1M / Seed / Sep 05, 2024
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. $43.1M / Series C / Mar 09, 2023
SIYO Bio-Tech SIYO Bio-Tech
SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology. $31.7M / Series B / Feb 23, 2022
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. Venture - Series Unknown / Dec 31, 2021
Zhaoke Ophthalmology Pharmaceutical Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform. $145M / Series B / Oct 12, 2020
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $5.1M / Post-IPO Equity / Mar 20, 2017
CloudClip CloudClip
CloudClip is a technology company that focuses on researching the myopia problem in young people and providing systematic solutions. They provide each user with customized eye-care training programs and help children develop a healthy eye-use habit. $1.4M / Series A / Dec 31, 2016
Qihoo 360 Technology Qihoo 360 Technology
Qihoo 360 Technology Co Ltd (Qihoo 360), formerly Qihoo Technology Company Limited, is engaged in the operations of Internet services and sales of third party anti-virus software in the People's Republic of China. It provides Internet and mobile security products in China. In January 2011, the Company had 328 million monthly active Internetsecurity product users, representing a user penetration rate of 83.9% in China. Its Internet and mobile security products include 360 Safe Guard and 360 Anti-virus, the Internet security products in China, with 301 million and 248 million monthly active users in January 2011, and 360 Mobile Safe, the mobile security product in China. The Company generates revenues primarily through offering the services, such as online advertising and Internet value-added services. Online advertising offers advertising services by providing marketing opportunities on its Websites and secure platform products to its advertising customers. $30M / Post-IPO Equity / Sep 28, 2016
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $7.1M / Series D / Jul 20, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Andorra
Guernsey
Cameroon
Sudan
Colombia
China
Armenia
Kenya
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Botswana
Moldova
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Aier Eye Hospital Group invest in?

Aier Eye Hospital Group invests primarily in Medical Device, Medical and Software startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Aier Eye Hospital Group?

Public channels for Aier Eye Hospital Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Aier Eye Hospital Group?

The team at Aier Eye Hospital Group includes Bang Chen (Founder), Li Li (Founder) and Michael Lau (CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Aier Eye Hospital Group Aier Eye Hospital Group Find emails